Alluvi, initially dubbed LY3414901, represents a significant advancement in weight management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target https://alluvi-healthcare472048.soro-blog.com/653432/alluvi-a-deep-dive-into-retatrutide-s-promise